Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Review

FRMD3 gene: its role in diabetic kidney disease. A narrative review

Authors: Marjoriê Piuco Buffon, Denise Alves Sortica, Fernando Gerchman, Daisy Crispim, Luís Henrique Canani

Published in: Diabetology & Metabolic Syndrome | Issue 1/2015

Login to get access

Abstract

Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus, which is considered a worldwide epidemic. Several studies have been developed in order to elucidate possible genetic factors involved in this disease. The FRMD3 gene, a strong candidate selected from genome wide association studies (GWAS), encodes the structural protein 4.1O involved in maintaining cell shape and integrity. Some single nucleotide polymorphisms (SNPs) located in FRMD3 have been associated with DKD in different ethnicities. However, despite these findings, the matter is still controversial. The aim of this narrative review is to summarize the evidence regarding the role of FRMD3 in DKD.
Literature
1.
Association AD. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef
2.
Association AD. Standards of medical care in diabetes: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.
3.
Sortica DA, et al. The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol. 2011;55(9):677–85.PubMedCrossRef
4.
Levey AS, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.PubMedCrossRef
5.
6.
Bruno RM, Gross JL. Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Compl. 2000;14(5):266–71.CrossRef
7.
de Boer IH et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 305(24):2532–9
8.
Dwyer JP et al. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardiorenal Med. 2(1): 1–10.
9.
Kramer H. Screening for kidney disease in adults with diabetes and prediabetes. Curr Opin Nephrol Hypertens. 2005;14(3):249–52.PubMedCrossRef
10.
Kramer CK, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30(8):1998–2000.PubMedCrossRef
11.
Ada ADA. Standards of medical care in diabetes–2006. Diabetes Care. 2006;29(Suppl 1):S4–42.
12.
ADA. Standards of medical care in diabetes–2013. Diabetes Care. 36(Suppl 1): S11–66.
13.
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.PubMedCrossRef
14.
KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012; Suppl: S1–S150.
15.
Chaturvedi N, et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60(1):219–27.PubMedCrossRef
16.
Adler AI, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMedCrossRef
17.
Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55(4):1582–96.PubMedCrossRef
18.
Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49(9):1399–408.PubMedCrossRef
19.
Perkins BA, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–93.PubMedCrossRef
20.
Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48(4):909–13.PubMedCrossRef
21.
Yajima Y, Nakajima S. Familial clustering and genetics of diabetic nephropathy. Nihon Rinsho. 1997;55(Suppl):795–801.PubMed
22.
Martini S, et al. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord. 2008;9(4):267–74.PubMedPubMedCentralCrossRef
23.
24.
25.
26.
Maeda S, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes. 2010;59(8):2075–9.PubMedPubMedCentralCrossRef
27.
Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med. 2005;5(5):509–25.PubMedCrossRef
28.
Freedman BI, et al. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306–16.PubMedCrossRef
29.
30.
Williams WW, et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes. 2012;61(8):2187–94.PubMedPubMedCentralCrossRef
31.
Lohmueller KE, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2):177–82.PubMedCrossRef
32.
Carpena MP, et al. Genetics of diabetic nephropathy. Arq Bras Endocrinol Metabol. 2010;54(3):253–61.PubMedCrossRef
33.
34.
McKnight AJ, McKay V, Maxwell AP. Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 21(3): 287–96.
35.
Ni X, et al. Molecular cloning and characterization of the protein 4.1O gene, a novel member of the protein 4.1 family with focal expression in ovary. J Hum Genet. 2003;48(2):101–6.PubMedCrossRef
36.
Hoover KB, Bryant PJ. The genetics of the protein 4.1 family: organizers of the membrane and cytoskeleton. Curr Opin Cell Biol. 2000;12(2):229–34.PubMedCrossRef
37.
Ramez M, et al. Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. Kidney Int. 2003;63(4):1321–37.PubMedCrossRef
38.
Chishti AH, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci. 1998;23(8):281–2.PubMedCrossRef
39.
Baines AJ. A FERM-adjacent (FA) region defines a subset of the 4.1 superfamily and is a potential regulator of FERM domain function. BMC Genom. 2006;7:85.CrossRef
40.
Takakuwa Y. Protein 4.1, a multifunctional protein of the erythrocyte membrane skeleton: structure and functions in erythrocytes and nonerythroid cells. Int J Hematol. 2000;72(3):298–309.PubMed
41.
Pasternack GR, et al. Interactions between protein 4.1 and band 3. An alternative binding site for an element of the membrane skeleton. J Biol Chem. 1985;260(6):3676–83.PubMed
42.
Lombardo CR, Willardson BM, Low PS. Localization of the protein 4.1-binding site on the cytoplasmic domain of erythrocyte membrane band 3. J Biol Chem. 1992;267(14):9540–6.PubMed
43.
Marfatia SM, et al. Identification of the protein 4.1 binding interface on glycophorin C and p55, a homologue of the Drosophila discs-large tumor suppressor protein. J Biol Chem. 1995;270(2):715–9.PubMedCrossRef
44.
Nunomura W, et al. Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin. Implications for modulation of CD44-ankyrin interaction. J Biol Chem. 1997;272(48):30322–8.PubMedCrossRef
45.
Schischmanoff PO, et al. Defining of the minimal domain of protein 4.1 involved in spectrin-actin binding. J Biol Chem. 1995;270(36):21243–50.PubMedCrossRef
46.
Walensky LD, et al. The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1. J Cell Biol. 1998;141(1):143–53.PubMedPubMedCentralCrossRef
47.
Mattagajasingh SN, et al. A nonerythroid isoform of protein 4.1R interacts with the nuclear mitotic apparatus (NuMA) protein. J Cell Biol. 1999;145(1):29–43.PubMedPubMedCentralCrossRef
48.
Kramer-Zucker AG, et al. Organization of the pronephric filtration apparatus in zebrafish requires Nephrin, Podocin and the FERM domain protein Mosaic eyes. Dev Biol. 2005;285(2):316–29.PubMedPubMedCentralCrossRef
49.
Wei X, et al. Kindlin-2 regulates renal tubular cell plasticity by activation of Ras and its downstream signaling. Am J Physiol Renal Physiol. 2013;306(2):F271–8.PubMedCrossRef
50.
Martini S, et al. From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes. 2013;62(7):2605–12.PubMedPubMedCentralCrossRef
51.
Pezzolesi MG, et al. Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy. PLoS One. 2013;8(3):e60301.PubMedPubMedCentralCrossRef
52.
Dolan V, Hensey C, Brady HR. Diabetic nephropathy: renal development gone awry? Pediatr Nephrol. 2003;18(2):75–84.PubMed
53.
54.
Palmer ND, Freedman BI. Diabetic nephropathy: FRMD3 in diabetic nephropathy–guilt by association. Nat Rev Nephrol. 2013;9(6):313–4.PubMedCrossRef
55.
Freedman BI, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011;7(6):e1002150.PubMedPubMedCentralCrossRef
56.
Park H, et al. A family-based association study after genome-wide linkage analysis identified two genetic loci for renal function in a Mongolian population. Kidney Int. 2013;83(2):285–92.PubMedCrossRef
57.
Palmer ND, et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One. 2014;9(2):e88273.PubMedPubMedCentralCrossRef
58.
Pezzolesi, M.G., et al., An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int. 80(1): 105–11.
Metadata
Title
FRMD3 gene: its role in diabetic kidney disease. A narrative review
Authors
Marjoriê Piuco Buffon
Denise Alves Sortica
Fernando Gerchman
Daisy Crispim
Luís Henrique Canani
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-015-0114-4

Other articles of this Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue

Research

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

Research

IRS-1 gene polymorphism and DNA damage in pregnant women with diabetes or mild gestational hyperglycemia

Research

Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population

Research

Glycemic variability in normal glucose tolerance women with the previous gestational diabetes mellitus

Review

Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

Research

Health-related quality of life in patients with type 1 diabetes mellitus in the different geographical regions of Brazil: data from the Brazilian Type 1 Diabetes Study Group
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits